Singapore
Initiatives being introduced in Taiwan, Hong Kong, and Singapore use AI and mobile technologies.
Latest studies have demonstrated high AI accuracies in predicting cancer recurrence and spotting minor colon polyps.
The app has demonstrated 93% accuracy in a nationwide study involving nearly 1,800 seniors.
Also, OMRON in Singapore has launched a new medical device plan featuring AI-driven recommendations for self-management of chronic diseases.
Selected early versions will be slated for real-world deployment.
NUS Medicine’s latest model has outperformed DNA-based biological ageing clocks and demonstrated a stronger capability to predict mortality.
What they offer is not a passive but an active clinical assistant that thinks beyond consultation notes.
Also, VUNO has obtained regulatory clearance in South Korea for its AI-based screening solution for kidney failure.
Also, fellow Korean medical AI companies have obtained regulatory approvals across global markets.
Also, Lytus adds an AI-driven blood logistics platform to its health technology portfolio.